ReviewBMC neurology2011
Neuroregeneration in neurodegenerative disorders.
Review in BMC neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Quercetin as a Hypothesized Involvement of VMAT2 in Neurodegenerative Diseases-Mechanistic Insight and Therapeutic Applications.Molecular neurobiology · 2026Review
- N 6 -methyladenosine modification regulates cell death in cognitive impairment.Neural regeneration research · 2026Article
- Human Mesenchymal Stromal Cells Induced In Vitro toward a Neurogenic Direction Temporarily Increase the Expression of NES, NSE, CHAT, and MAP2 Genes without Changing the Basic Immunophenotype.Bulletin of experimental biology and medicine · 2026Article
- Exploration of the Neuromodulatory Properties of Fyn and GSK-3β Kinases Exploiting 7-Azaindole-Based Inhibitors.Journal of medicinal chemistry · 2025Article
- Brain structural alterations and cognitive dysfunction in lung cancer patients without brain metastasis.Scientific reports · 2025Article
- Exploring Indole-Based Molecules as Novel Therapeutics for Parkinson's Disease: A Comprehensive Review.Mini reviews in medicinal chemistry · 2025Review
- Targeting neuroplasticity: a viewpoint on a future research direction with Parkinson's disease-related fatigue.Frontiers in aging neuroscience · 2025Article
- Neuroplasticity in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Psychedelic LSD activates neurotrophic signal but fails to stimulate neural stem cells.Stem cell research & therapy · 2024Article
- GenusInternational journal of molecular sciences · 2024Review
- Potential Plausible Role of Stem Cell for Treating Depressive Disorder: a Retrospective Review.Molecular neurobiology · 2024Review
- Therapeutic potential and mechanisms of stem cells in major depressive disorder: a comprehensive review.Frontiers in pharmacology · 2024Review
- Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024Article
- Artificial Intelligence in The Management of Neurodegenerative Disorders.CNS & neurological disorders drug targets · 2024Review
- Editorial: Natural products for neuroprotection and neuroregeneration.Frontiers in pharmacology · 2023Article
- Review
- Self-Assembling Hydrogel Structures for Neural Tissue Repair.ACS biomaterials science & engineering · 2021Review
- Knockdown of astrocytic Grin2a aggravates β-amyloid-induced memory and cognitive deficits through regulating nerve growth factor.Aging cell · 2021Article
- The Neurotrophic-Like Effect of Carvacrol: Perspective for Axonal and Synaptic Regeneration.Neurotoxicity research · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroregeneration is a relatively recent concept that includes neurogenesis, neuroplasticity, and neurorestoration--implantation of viable cells as a therapeutical approach. DISCUSSION: Neurogenesis and neuroplasticity are impaired in brains of patients suffering from Alzheimer's Disease or Parkinson's Disease and correlate with low endogenous protection, as a result of a diminished growth factors expression. However, we hypothesize that the brain possesses, at least in early and medium stages of disease, a "neuroregenerative reserve", that could be exploited by growth factors or stem cells-neurorestoration therapies. SUMMARY: In this paper we review the current data regarding all three aspects of neuroregeneration in Alzheimer's Disease and Parkinson's Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.